CSPC Pharmaceutical Group Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from CSPC Pharmaceutical Group Limited's yearly results (2022–2025), compared with companies in China. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ¥100 of reported profit came with ¥103 of operating cash. Lower than 94% of companies in China.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 0 of 3. Less steady than 90% of companies in China.
- Debt Due Cover Ratio: Debt due within a year is covered 17.7 times by its yearly operating cash. Higher than 87% of companies in China.
Where ¥100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥103Over the last 3 years, every ¥100 of reported profit came with ¥103 of operating cash.
Lower than 94% of companies in China.
Self-Funding Ratio
2.1×Over the last 3 years its own operating cash covered its investment spending (capex) 2.1 times.
Lower than 57% of companies in China.
Cash Locked Ratio
−¥4Money owed to suppliers is larger than money owed by customers plus stock: ¥4 per ¥100 of sales comes from others' credit, against ¥4 from others' credit three years earlier.
Less money tied up than 51% of companies in China.
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 90% of companies in China.
Growth Efficiency Ratio
—Sales fell 16%
Sales fell 16% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-16% / +12%In 3 years sales changed by -16% while total assets changed by +12%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
17.7×Debt due within a year is covered 17.7 times by its yearly operating cash.
Higher than 87% of companies in China.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
94%Of every ¥100 the company owns, ¥94 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 71% of companies in China.
Tangible Net Worth Ratio
91%Of every ¥100 of net worth, ¥91 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 60% of companies in China.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
CSPC Pharmaceutical Group Limited owes ¥0.30 for every ¥1 it owns. Net profit fell 10% in the year to Dec 2025, and shrank 14% a year on average over 3 years.
Compared with companies in China · latest annual results Dec 2025.
P/E ratio
11.9Investors pay ¥11.9 for every ¥1 of CSPC Pharmaceutical Group Limited's yearly profit, lower than 55% of companies in China.
P/B ratio
2.15The share price is 2.15 times CSPC Pharmaceutical Group Limited's book value per share, higher than 62% of companies in China.
Market cap
HK$95.3 BThe total market value of all of CSPC Pharmaceutical Group Limited's shares at today's price (share price × number of shares), smaller than 68% of companies in China. PosiCap size class: Tito Cap.
Net worth (book value)
¥37.6 BWhat CSPC Pharmaceutical Group Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Return on equity (ROE)
20.9%CSPC Pharmaceutical Group Limited earned 20.9% on its shareholders' money over the last year, higher than 75% of companies in China.
Owes vs Owns
0.30×CSPC Pharmaceutical Group Limited owes ¥0.30 for every ¥1 it owns (low), lower than 89% of companies in China.
Dividend yield
4.14%CSPC Pharmaceutical Group Limited pays 4.14% of its share price as dividends a year, higher than 50% of dividend-paying companies in China.
Revenue growth
-10%Revenue fell 10% in the year to Dec 2025, and shrank 6% a year on average over 3 years.
Profit growth
-10%Net profit fell 10% in the year to Dec 2025, and shrank 14% a year on average over 3 years.
Profit margin
14.9%CSPC Pharmaceutical Group Limited keeps ¥15 of every ¥100 of revenue as net profit.
Cash quality
1.5×Cash from CSPC Pharmaceutical Group Limited's business was 1.5× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
108.3×CSPC Pharmaceutical Group Limited's operating profit covered its interest costs 108.3 times in the year to Dec 2025.
Cash vs debt
Net cashCSPC Pharmaceutical Group Limited held ¥8.2 B more cash than debt (net cash) at Dec 2025.
Questions
What is CSPC Pharmaceutical Group Limited's P/E ratio?
Investors pay ¥11.9 for every ¥1 of CSPC Pharmaceutical Group Limited's yearly profit, lower than 55% of companies in China.
What is CSPC Pharmaceutical Group Limited's return on equity?
CSPC Pharmaceutical Group Limited earned 20.9% on its shareholders' money over the last year, higher than 75% of companies in China.
How much does CSPC Pharmaceutical Group Limited owe compared with what it owns?
CSPC Pharmaceutical Group Limited owes ¥0.30 for every ¥1 it owns (low), lower than 89% of companies in China.
Does CSPC Pharmaceutical Group Limited pay a dividend?
Yes. CSPC Pharmaceutical Group Limited pays 4.14% of its share price as dividends a year, higher than 50% of dividend-paying companies in China.
Is CSPC Pharmaceutical Group Limited's revenue growing?
Revenue fell 10% in the year to Dec 2025, and shrank 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.